Neurophth Overview

  • Founded
  • 2016
  • Status
  • Private
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $18.4M
Latest Deal Amount
  • Investors
  • 5

Neurophth General Information


Developer of gene therapies for ophthalmological disorders. The company's therapies aim to cure disorders such as Leber's hereditary optic neuropathy caused by genetic mutation, enabling physicians to prescribe more effective treatments to their patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • Room C270-C271, Floor 3, Building B1, Wuhan National Bio-industry Base
  • No.666 Gaoxin Avenue, East Lake New Technology Development Zone
  • Wuhan, Hubei 430000
  • China
+86 027 0000 0000

Neurophth Timeline

Date FoundedFinancing RoundFinancing Round
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Neurophth Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 08-Apr-2020 $18.4M 000.00 0000 Completed Pre-Clinical Trials
1. Early Stage VC 16-Aug-2018 Completed Startup
To view Neurophth’s complete valuation and funding history, request access »

Neurophth Executive Team (1)

Name Title Board Seat Contact Info
Su Xiao Chief Executive Officer & Founder
To view Neurophth’s complete executive team members history, request access »

Neurophth Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Fosun InnoStar Venture Corporate Venture Capital Minority 000 0000 000000 0
Sequoia Capital China Venture Capital Minority 000 0000 000000 0
BGI Co-Win Corporate Venture Capital Minority 000 0000 000000 0
BOHE Angel Fund Venture Capital Minority 000 0000 000000 0
Northern Light Venture Capital Venture Capital Minority 000 0000 000000 0
To view Neurophth’s complete investors history, request access »